, Evaluation of both exonic and intronic variants for effects on RNA splicing allows for accurate assessment of the effectiveness of precision therapies, PLoS Genet, vol
The Takeaway The new report doesnt revolutionize diabetes careit refines it
Improvements in visceral adiposity exceeded those observed in the comparator group receiving a sodium-glucose cotransporter 2 (SGLT2) inhibitor
Hlscher C (2022) Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimers and Parkinsons diseases
Lilly CEO David Ricks framed the approval in terms of access: " Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn't serious enough for treatment, " Ricks said in the company's April 1 press release
A lot of GLP-1 side effects are really meal-composition problems
